[{"orgOrder":0,"company":"University of Nairobi","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"KENYA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bictegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"University of Nairobi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"University of Nairobi \/ Gilead Sciences","highestDevelopmentStatusID":"11","companyTruncated":"University of Nairobi \/ Gilead Sciences"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bictegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ Gilead Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Peking Union Medical College Hospital \/ Gilead Sciences"},{"orgOrder":0,"company":"National Center for AIDS\/STD Control and Prevention, China CDC","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bictegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"National Center for AIDS\/STD Control and Prevention, China CDC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Center for AIDS\/STD Control and Prevention, China CDC \/ Gilead Sciences","highestDevelopmentStatusID":"11","companyTruncated":"National Center for AIDS\/STD Control and Prevention, China CDC \/ Gilead Sciences"},{"orgOrder":0,"company":"Chelsea and Westminster NHS Trust","sponsor":"Gilead Sciences | Imperial College London","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bictegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Chelsea and Westminster NHS Trust","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chelsea and Westminster NHS Trust \/ Gilead Sciences | Imperial College London","highestDevelopmentStatusID":"11","companyTruncated":"Chelsea and Westminster NHS Trust \/ Gilead Sciences | Imperial College London"},{"orgOrder":0,"company":"Chelsea and Westminster NHS Trust","sponsor":"Imperial College London | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bictegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Chelsea and Westminster NHS Trust","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chelsea and Westminster NHS Trust \/ Imperial College London | Gilead Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Chelsea and Westminster NHS Trust \/ Imperial College London | Gilead Sciences"},{"orgOrder":0,"company":"Quest Clinical Research","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bictegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Quest Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quest Clinical Research \/ Gilead Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Quest Clinical Research \/ Gilead Sciences"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bictegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Denver \/ Gilead Sciences","highestDevelopmentStatusID":"11","companyTruncated":"University of Colorado, Denver \/ Gilead Sciences"},{"orgOrder":0,"company":"University of Miami","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bictegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Miami \/ Gilead Sciences","highestDevelopmentStatusID":"11","companyTruncated":"University of Miami \/ Gilead Sciences"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Trutag Technologies | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bictegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Brigham and Women's Hospital \/ Trutag Technologies | Gilead Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Brigham and Women's Hospital \/ Trutag Technologies | Gilead Sciences"},{"orgOrder":0,"company":"University of Missouri-Columbia","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bictegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"University of Missouri-Columbia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Missouri-Columbia \/ Gilead Sciences","highestDevelopmentStatusID":"11","companyTruncated":"University of Missouri-Columbia \/ Gilead Sciences"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bictegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Weill Medical College of Cornell University \/ Gilead Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Weill Medical College of Cornell University \/ Gilead Sciences"},{"orgOrder":0,"company":"East Carolina University","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bictegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"East Carolina University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"East Carolina University \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"11","companyTruncated":"East Carolina University \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bictegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bictegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bictegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bictegravir","moa":"HIV-1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Haitian Group for Study of Kaposi's Sarcoma","sponsor":"Brigham and Women's Hospital | Harvard Medical School (HMS and HSDM) | Analysis Group | Weill Medical College of Cornell University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HAITI","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bictegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Haitian Group for Study of Kaposi's Sarcoma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Haitian Group for Study of Kaposi's Sarcoma \/ Brigham and Women's Hospital | Harvard Medical School (HMS and HSDM) | Analysis Group | Weill Medical College of Cornell University","highestDevelopmentStatusID":"11","companyTruncated":"Haitian Group for Study of Kaposi's Sarcoma \/ Brigham and Women's Hospital | Harvard Medical School (HMS and HSDM) | Analysis Group | Weill Medical College of Cornell University"},{"orgOrder":0,"company":"Tulika Singh, MD","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bictegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Tulika Singh, MD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tulika Singh, MD \/ Gilead Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Tulika Singh, MD \/ Gilead Sciences"},{"orgOrder":0,"company":"Carmen Hidalgo Tenorio","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bictegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Carmen Hidalgo Tenorio","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmen Hidalgo Tenorio \/ Gilead Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Carmen Hidalgo Tenorio \/ Gilead Sciences"},{"orgOrder":0,"company":"Judit Pich Mart\u00ednez","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bictegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Judit Pich Mart\u00ednez","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Judit Pich Mart\u00ednez \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Judit Pich Mart\u00ednez \/ Gilead Sciences"}]
Find Clinical Drug Pipeline Developments & Deals for Bictegravir
Details :
Bictegravir is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of HIV Infections.
Details :
Bictegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of HIV Infections.
Details :
Bictegravir is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of HIV Infections.
Details :
Bictegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of HIV Infections.
Details :
Bictegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of HIV Infections.
Details :
Bictegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of HIV Infections.
Details :
Bictegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of HIV Infections.
Details :
Bictegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of HIV Infections.
Details :
Bictegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of HIV Infections.
Details :
Bictegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of HIV Infections.
Reset All
